Strike two: Vical says another one of its vaccines has crashed and burned in PhII
Another development program has run up onto the rocks at Vical $VICL.
Five months after the San Diego-based biotech was forced to restructure in the aftermath of a critical Phase II failure, one of the two clinical programs it turned to in the wake of that setback has also been scrapped. And the fresh fail drove its shares down 29% before the open.
Researchers say that their bivalent vaccine candidate for herpes simplex virus type 2 failed to beat a placebo on the recurrence of lesions among 261 patients recruited for the study. And like the CMV vaccine ASP0113, the biotech is opting to wash its hands of the whole effort now.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
